Mindset Pharma to Participate in Upcoming Conferences in April 2022

Rhea-AI Summary

Mindset Pharma Inc. (CSE: MSET, FSE: 9DF, OTCQB: MSSTF) announced CEO James Lanthier's participation in two upcoming virtual conferences. The Sequire Cannabis & Psychedelic Conference will take place on April 20, 2022, with Lanthier presenting at 2:30 p.m. ET. The KCSA Psychedelics Investor Conference is set for April 27-28, 2022, where he will speak on April 28 at 10:00 a.m. ET. Mindset focuses on developing next-generation psychedelic medicines for neurological and psychiatric disorders.

TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that James Lanthier, CEO of Mindset, will participate in two upcoming conferences:

• Sequire Cannabis & Psychedelic Conference to be held virtually on Wednesday, April 20, 2022. Mr. Lanthier will present at 2:30 p.m. ET. To attend, register here.
  
• KCSA Psychedelics Investor Conference to be held virtually on April 27-28, 2022. Mr. Lanthier will present on Thursday, April 28^th at 10:00 a.m. ET. To attend, register here.
  

For more information about the conferences, or to schedule a one-on-one meeting with Mindset management, please contact your appropriate representative directly, or send an email to KCSA Strategic Communications at Mindset@kcsa.com.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FAQ

When is Mindset Pharma participating in the Sequire Cannabis & Psychedelic Conference?

Mindset Pharma will participate in the Sequire Cannabis & Psychedelic Conference on April 20, 2022, with CEO James Lanthier presenting at 2:30 p.m. ET.

What date will James Lanthier speak at the KCSA Psychedelics Investor Conference?

James Lanthier will present at the KCSA Psychedelics Investor Conference on April 28, 2022, at 10:00 a.m. ET.

What is the focus of Mindset Pharma's drug development?

Mindset Pharma focuses on developing optimized and patentable next-generation psychedelic medicines for treating neurological and psychiatric disorders.

What are the main objectives of Mindset Pharma Inc.?

Mindset Pharma aims to create novel psychedelic compounds and an innovative process for synthesizing psilocybin, addressing unmet medical needs in psychiatric treatment.

How can I register for the upcoming Mindset Pharma conferences?

You can register for the Sequire Cannabis & Psychedelic Conference [here](https://cannabis-conference22.mysequire.com/) and for the KCSA Psychedelics Investor Conference [here](https://www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference-0).